Zentalis Pharmaceuticals (ZNTL) Competitors

$4.09 +0.09 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 +0.01 (+0.34%)

As of 04:17 PM Eastern

ZNTL vs. QURE, EVO, SEPN, DBVT, and COLL

Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include uniQure (QURE), Evotec (EVO), Septerna (SEPN), DBV Technologies (DBVT), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Zentalis Pharmaceuticals compare to uniQure?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

: In the previous week, uniQure had 20 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 23 mentions for uniQure and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.97 beat uniQure's score of 0.59 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
uniQure
6 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
: Zentalis Pharmaceuticals presently has a consensus price target of $5.83, indicating a potential upside of 42.62%. uniQure has a consensus price target of $44.50, indicating a potential upside of 110.30%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Zentalis Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zentalis Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.29
uniQure
1 Sell rating(s)

6 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.53
: Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
: Zentalis Pharmaceuticals has a net margin of 0.00% compared to uniQure's net margin of -1,236.00%. Zentalis Pharmaceuticals' return on equity of -52.77% beat uniQure's return on equity.
Company Net Margins Return on Equity Return on Assets
Zentalis Pharmaceuticals N/A -52.77% -40.55%
uniQure -1,236.00% -174.03% -27.41%
: Zentalis Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zentalis Pharmaceuticals $67.43M 4.30 -$137.06M -$1.90 N/A
uniQure $16.10M 82.90 -$198.97M -$3.45 N/A
: 78.8% of uniQure shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	6 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-52.77%	-40.55%
uniQure	-1,236.00%	-174.03%	-27.41%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.30	-$137.06M	-$1.90	N/A
uniQure	$16.10M	82.90	-$198.97M	-$3.45	N/A

Summary

Zentalis Pharmaceuticals beats uniQure on 9 of the 17 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Evotec?

Evotec (NASDAQ:EVO) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

: In the previous week, Evotec had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 5 mentions for Evotec and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.97 beat Evotec's score of 0.28 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Evotec has higher revenue and earnings than Zentalis Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evotec $788.37M 1.44 -$117.12M N/A N/A
Zentalis Pharmaceuticals $67.43M 4.30 -$137.06M -$1.90 N/A
: 5.8% of Evotec shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Evotec currently has a consensus price target of $7.00, indicating a potential upside of 118.75%. Zentalis Pharmaceuticals has a consensus price target of $5.83, indicating a potential upside of 42.62%. Given Evotec's stronger consensus rating and higher possible upside, research analysts plainly believe Evotec is more favorable than Zentalis Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Zentalis Pharmaceuticals
1 Sell rating(s)

4 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.29
: Zentalis Pharmaceuticals has a net margin of 0.00% compared to Evotec's net margin of -13.13%. Evotec's return on equity of -12.40% beat Zentalis Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Evotec -13.13% -12.40% -5.77%
Zentalis Pharmaceuticals N/A -52.77% -40.55%
: Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$788.37M	1.44	-$117.12M	N/A	N/A
Zentalis Pharmaceuticals	$67.43M	4.30	-$137.06M	-$1.90	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-13.13%	-12.40%	-5.77%
Zentalis Pharmaceuticals	N/A	-52.77%	-40.55%

Summary

Evotec beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

: Septerna has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Septerna $45.95M 23.58 -$48.88M -$1.11 N/A
Zentalis Pharmaceuticals $67.43M 4.30 -$137.06M -$1.90 N/A
: Zentalis Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -106.37%. Septerna's return on equity of -15.85% beat Zentalis Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Septerna -106.37% -15.85% -11.96%
Zentalis Pharmaceuticals N/A -52.77% -40.55%
: In the previous week, Septerna had 3 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 6 mentions for Septerna and 3 mentions for Zentalis Pharmaceuticals. Septerna's average media sentiment score of 1.12 beat Zentalis Pharmaceuticals' score of 0.97 indicating that Septerna is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Septerna has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
: Septerna currently has a consensus price target of $43.13, indicating a potential upside of 78.72%. Zentalis Pharmaceuticals has a consensus price target of $5.83, indicating a potential upside of 42.62%. Given Septerna's stronger consensus rating and higher probable upside, equities analysts clearly believe Septerna is more favorable than Zentalis Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.80
Zentalis Pharmaceuticals
1 Sell rating(s)

4 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.29

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	23.58	-$48.88M	-$1.11	N/A
Zentalis Pharmaceuticals	$67.43M	4.30	-$137.06M	-$1.90	N/A

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-106.37%	-15.85%	-11.96%
Zentalis Pharmaceuticals	N/A	-52.77%	-40.55%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29

Summary

Septerna beats Zentalis Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

: DBV Technologies currently has a consensus target price of $40.25, indicating a potential upside of 106.52%. Zentalis Pharmaceuticals has a consensus target price of $5.83, indicating a potential upside of 42.62%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe DBV Technologies is more favorable than Zentalis Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
2 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.67
Zentalis Pharmaceuticals
1 Sell rating(s)

4 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.29
: In the previous week, DBV Technologies had 15 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 18 mentions for DBV Technologies and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.97 beat DBV Technologies' score of 0.03 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
3 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Zentalis Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Zentalis Pharmaceuticals' return on equity of -52.77% beat DBV Technologies' return on equity.
Company Net Margins Return on Equity Return on Assets
DBV Technologies -2,895.37% -129.88% -88.84%
Zentalis Pharmaceuticals N/A -52.77% -40.55%
: 71.7% of DBV Technologies shares are owned by institutional investors. 1.4% of DBV Technologies shares are owned by insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Zentalis Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV Technologies N/A N/A -$146.95M -$4.46 N/A
Zentalis Pharmaceuticals $67.43M 4.30 -$137.06M -$1.90 N/A
: DBV Technologies has a beta of -0.97, indicating that its share price is 197% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Zentalis Pharmaceuticals	N/A	-52.77%	-40.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A
Zentalis Pharmaceuticals	$67.43M	4.30	-$137.06M	-$1.90	N/A

Summary

Zentalis Pharmaceuticals beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

: Collegium Pharmaceutical has a net margin of 8.05% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 98.65% beat Zentalis Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical 8.05% 98.65% 15.86%
Zentalis Pharmaceuticals N/A -52.77% -40.55%
: Collegium Pharmaceutical currently has a consensus target price of $53.40, indicating a potential upside of 51.02%. Zentalis Pharmaceuticals has a consensus target price of $5.83, indicating a potential upside of 42.62%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than Zentalis Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
3 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.57
Zentalis Pharmaceuticals
1 Sell rating(s)

4 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.29
: Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.
: Collegium Pharmaceutical has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Collegium Pharmaceutical $780.57M 1.47 $62.87M $1.71 20.68
Zentalis Pharmaceuticals $67.43M 4.30 -$137.06M -$1.90 N/A
: In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 1 mentions for Collegium Pharmaceutical. Zentalis Pharmaceuticals' average media sentiment score of 0.97 beat Collegium Pharmaceutical's score of -0.21 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Collegium Pharmaceutical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	8.05%	98.65%	15.86%
Zentalis Pharmaceuticals	N/A	-52.77%	-40.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.47	$62.87M	$1.71	20.68
Zentalis Pharmaceuticals	$67.43M	4.30	-$137.06M	-$1.90	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Collegium Pharmaceutical beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.10M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-2.15	38.85	29.04	28.47
Price / Sales	4.30	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	1.37	7.03	9.67	6.67
Net Income	-$137.06M	$23.62M	$3.55B	$332.53M
7 Day Performance	0.99%	3.68%	1.70%	2.01%
1 Month Performance	55.51%	7.16%	5.62%	9.19%
1 Year Performance	200.74%	67.05%	34.41%	39.59%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	3.0048 of 5 stars	$4.09 +2.3%	$5.83 +42.6%	N/A	$290.10M	$67.43M	N/A	160
QURE uniQure	2.783 of 5 stars	$17.90 -0.7%	$42.83 +139.3%	N/A	$1.13B	$16.10M	N/A	500	Positive News Earnings Report Upcoming Earnings Analyst Forecast
EVO Evotec	2.1673 of 5 stars	$3.14 -0.3%	$7.00 +122.9%	N/A	$1.12B	$891.97M	N/A	4,553	Upcoming Earnings
SEPN Septerna	2.5754 of 5 stars	$25.09 +1.7%	$43.14 +72.0%	N/A	$1.11B	$45.95M	N/A	N/A	Positive News
DBVT DBV Technologies	2.7682 of 5 stars	$20.39 +3.0%	$38.65 +89.6%	N/A	$1.10B	$5.64M	N/A	80	Trending News Earnings Report Analyst Upgrade Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. QURE, EVO, SEPN, DBVT, and COLL

How does Zentalis Pharmaceuticals compare to uniQure?

Summary

How does Zentalis Pharmaceuticals compare to Evotec?

Summary

How does Zentalis Pharmaceuticals compare to Septerna?

Summary

How does Zentalis Pharmaceuticals compare to DBV Technologies?

Summary

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. QURE, EVO, SEPN, DBVT, and COLL

How does Zentalis Pharmaceuticals compare to uniQure?

Summary

How does Zentalis Pharmaceuticals compare to Evotec?

Summary

How does Zentalis Pharmaceuticals compare to Septerna?

Summary

How does Zentalis Pharmaceuticals compare to DBV Technologies?

Summary

How does Zentalis Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools